| News
GETEC acquires Infrapark Baselland
20.11.2018
The energy services provider GETEC is acquiring Infrapark Baselland AG and its activities from the chemicals company Clariant. GETEC also intends to acquire Novartis’s facilities in the neighbouring Schweizerhalle, thus boosting the site’s attractiveness.
Clariant, Infrapark Baselland AG and GETEC recently signed the agreement for the planned sale to GETEC, announced a statement from Infrapark Baselland AG. According to the terms, the transaction will be completed by the end of the year.
GETEC is also acquiring Novartis’s production and infrastructure facilities in the Schweizerhalle site. The move signals the creation of a “new and diversified industrial park with economic significance for the entire region”, writes the statement.
“We are very pleased to have found in GETEC an owner for Infrapark Baselland AG, which has the necessary know-how to operate, integrate and develop industrial parks. I am convinced that this step will give the Schweizerhalle location and thus the employees an attractive future perspective,” commented Oliver Kinkel, head of region Europe at Clariant, in the statement.
With GETEC as operator, Schweizerhalle will gain competitiveness as a chemical life science park and create better growth opportunities “for new companies operating on the site”. A first company has already signed to move into the Schweizerhalle in the coming year: the chemicals specialist Van Baerle. Following the sale, Clariant will also remain as a tenant in Infrapark Baselland.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Yokogawa establishes innovation center in Allschwil
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.
Read More
Basel gains new biotech in Bright Peak
Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.
Read More
Robots from Basel set to revolutionize surgery
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.
Read More
T3 Pharma raises over 25 million Swiss francs
T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.
Read More
Versameb raises 6 million Swiss francs
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.
Read More
Genedata accelerating drug development
Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.
Read More
Basel is “probably the most productive life sciences location in the world”
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.
Read More
Basel Area cantons publish joint economic report
The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.
Read More
Resistell receives high-level EU grant
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.
Read More
Switzerland Innovation Park Basel Area Site Novartis Campus
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.
Read More
